We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Near-Patient Molecular Diagnostics Forecasted to USD 1 Billion

By LabMedica International staff writers
Posted on 28 Mar 2016
Print article
Although currently the sector of point-of-care (POC) and near-patient molecular diagnostic solutions is less than USD 100 million, it is likely to grow to over USD 1 billion by 2020, according to a new healthcare market analysis.

Based on its latest study “The Market and Potential for Molecular Point of Care Diagnostics,” Kalorama Information (New York, NY, USA) said that investment in this test category and the market available in sectors where these tests compete suggest a much larger market. “There’s a large unmet need in the developed world for better testing solutions for upper respiratory infections and sexual health conditions,” said Kalorama editor Bruce Carlson, “and a large unmet need in the developing world for high-burden such as HIV and malaria, with efforts supported by fundraising.”

The major segments analyzed in the report include respiratory tract infections; women’s health and sexual health; high-burden diseases; gastrointestinal (GI), hospital-acquired (HAIs) and bloodstream infections (BSIs); and non-infectious disease testing for pharmacogenetics (PGx), hereditary genetics and cancer. Upper respiratory infections represent a large potential market and one of the most common reasons for patients to seek outpatient care. Complications from respiratory infections in young children and the elderly can also lead to emergency or inpatient care.

Rapid flu testing is a leading application for POC platforms. The first CLIA-waived molecular tests were for influenza and are now available for adoption by the entirety of the US physician office laboratory (POL) and other outpatient testers. Decentralized hospital labs also represent an initial target market. Group A Streptococcus (strep A) and respiratory syncytial virus (RSV) represent the next two leading target markets. Respiratory tract infections projected to develop into significant molecular POC diagnostics markets by 2020 are also included in the report.

In addition to well-developed tests for vaginitis, Group B Streptococcus (GBS) and STIs of Chlamydia (CT), gonorrhea (NG), herpes simplex virus (HSV) and human papillomavirus (HPV) have also been frequently targeted for molecular POC assay development.

POC products for human immunodeficiency virus (HIV), tuberculosis (TB), hepatitis, malaria and other tropical or neglected infectious diseases are expected to find significant markets in the developing world. Sales of infectious disease tests to the developing world are highly dependent upon concessional pricing by vendors; co-financing by international organizations and recipient national governments; and bulk procurement on the regional and national levels. Rapid immunoassay tests for HIV and malaria, for instance, are now sold low prices due to the above conditions as well as market consolidation. This report assumes that cost improvements will be made to molecular options and preferential pricing will be available by vendors.

Kalorama’s report also mentions expected healthcare developments in the developing world relevant to POC testing, such as the decentralization of TB testing and expansion of the global population receiving antiretroviral therapy. Other demand areas of testing projected to develop significantly by 2020 include gastrointestinal, hospital-acquired, and bloodstream infections.

The report provides market sizing and opportunity forecasts for all of these areas.

Related Links:

Kalorama Information
Report: The Market and Potential for Molecular Point-of-Care Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.